Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591187 | 0.81 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL28535462 | 0.78 | DGAT1 (0.44) | DGAT1ALDH1A1TSHRGGT1 | |
| SCHEMBL27482953 | 0.78 | DGAT1 (0.44) | DGAT1ALDH1A1TSHRGGT1 | |
| SCHEMBL27721975 | 0.78 | DGAT1 (0.44) | DGAT1ALDH1A1TSHRGGT1 | |
| SCHEMBL1486198 | 0.78 | DGAT1 (0.44) | DGAT1ALDH1A1TSHRGGT1 | |
| SCHEMBL27859821 | 0.78 | DGAT1 (0.44) | DGAT1ALDH1A1TSHRGGT1 | |
| SCHEMBL953572 | 0.77 | DGAT1 (0.40) | DGAT1ALDH1A1TSHR | |
| SCHEMBL10892362 | 0.77 | DGAT1 (0.48) | DGAT1ALDH1A1TSHR | |
| SCHEMBL1061233 | 0.77 | DGAT1 (0.48) | DGAT1ALDH1A1TSHR | |
| SCHEMBL27765256 | 0.75 | DGAT1 (0.46) | DGAT1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415831-B2 | HPLC free purification of peptides by the use of new capping and capture reagents | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20220064212-A1 | HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2022-03-03 | — | — | US | disclosed |
| EP-3908590-A1 | HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS | F. Hoffmann-La Roche AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| CN-113272316-A | HPLC-free purification of peptides using novel capping and capture reagents | 豪夫迈·罗氏有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020144111-A1 | HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-16 | — | — | WO | disclosed |
| US-9683006-B2 | Method of purifying/concentrating sugar chains with a sugar chain-trapping molecule and method of analyzing sugar chain structure | SUMITOMO BAKELITE CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3034495-A1 | COMPOUND FOR LABELLING SUGAR CHAIN SAMPLE | Sumitomo Bakelite Co.,Ltd. (JP) | 2016-06-22 | — | — | EP | disclosed |
| US-20160168196-A1 | COMPOUND FOR LABELING SUGAR CHAIN SAMPLE | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-9206225-B2 | Materials and methods for isolating phosphopeptides | PURDUE RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| US-6663869-B1 | Linkages between polypeptide organic molecules are oxime linkages formed by reaction of a keto, aldehyde or amino-oxy group on the amino acid | GRYPHON THERAPEUTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| WO-2003101425-A2 | THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES | ALNIS BIOSCIENCES, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20020159992-A1 | Antiangiogenic polypeptides and methods for inhibiting angiogenesis | ABBOTT LABORATORIES | 2002-10-31 | — | — | US | disclosed |
| US-6217873-B1 | HOMOGENEOUS; MEDICAL DIAGNOSIS | GRYPHON SCIENCES | 2001-04-17 | — | — | US | disclosed |
| US-6174530-B1 | Homogeneous polyoxime compositions and their preparation by parallel assembly | GRYPHON SCIENCES | 2001-01-16 | — | — | US | disclosed |
| EP-0697891-B1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | ROSE KEITH (CH) | 2000-03-29 | — | — | EP | disclosed |
| US-6001364-A | COMPRISING A BASEPLATE STRUCTURE HAVING A PLURALITY OF OXIME BONDS, WHEREIN EACH OXIME BOND LINKS A SPECIFICALLY ACTIVE MOLECULE TO THE BASEPLATE; FOR INDUCING AN IMMUNE RESPONSE IN AN ANIMAL | GRYPHON SCIENCES (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0697891-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | Rose, Keith (CH) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994025071-A1 | POLYOXIME COMPOUNDS AND THEIR PREPARATION | ROSE KEITH (CH) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415831-B2 | HPLC free purification of peptides by the use of new capping and capture reagents | RNGTT, PTMS, RNMT | DGAT1 3762/4885ALDH1A1 3698/4885TSHR 1392/4885 |
| US-20020159992-A1 | Antiangiogenic polypeptides and methods for inhibiting angiogenesis | VEGFA, HDGF, FLT4 | DGAT1 3682/4885ALDH1A1 3536/4885TSHR 3864/4885 |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | DGAT1 2509/4885ALDH1A1 4079/4885TSHR 2125/4885 |
| US-20220064212-A1 | HPLC FREE PURIFICATION OF PEPTIDES BY THE USE OF NEW CAPPING AND CAPTURE REAGENTS | RNGTT, PTMS, RNMT | DGAT1 3762/4885ALDH1A1 3698/4885TSHR 1392/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | DGAT1 2509/4885ALDH1A1 4079/4885TSHR 2125/4885 |
| US-20160168196-A1 | COMPOUND FOR LABELING SUGAR CHAIN SAMPLE | SLC2A4, SLC2A2, SLC2A1 | DGAT1 909/4885ALDH1A1 2734/4885TSHR 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.